Compass Therapeutics (CMPX) investor relations material

Pipeline overview and clinical progress

• Four antibody-based oncology drugs in the clinic by early next year, including bispecific and next-gen candidates.

• Lead program is a DLL4 VEGFA bispecific antibody in a randomized trial for advanced biliary tract cancer.

• Recent phase one data announced for a novel PD-1, PD-L1 bispecific with responses in post-checkpoint inhibitor patients.

• IND filing for a PD-1 VEGFA bispecific antibody on track for this quarter, with preclinical data presented at SITSI.

• Multiple clinical trial readouts expected in 2026, with funding secured into 2028.

COMPANION-002 study and commercial opportunity

• Second-line BTC market in the US estimated at 15,000 patients annually, representing a commercial opportunity exceeding $1 billion.

• COMPANION-002 trial showed statistically significant improvement in response rate by adding Tuvesimig to paclitaxel (p=0.031).

• Marked reduction in progressive disease at week eight in the combination arm (16.2% vs. 42.1% control).

• No new safety signals identified; study overseen by a data safety monitoring committee.

• Progression-free survival (PFS) and overall survival (OS) data expected in late Q1 next year.

Regulatory and clinical strategy

• Hierarchical testing used for endpoints; positive response rate allows full alpha to roll over to PFS and OS.

• Fewer deaths than projected suggest a possible survival benefit.

• FDA required paclitaxel as the control arm; FOLFOX not mandated despite NCCN guidelines.

• Market research indicates even modest clinical benefits would be meaningful to clinicians.